Myesha Lacy
Contacto de Relaciones con Inversores en ARCELLX, INC. .
Perfil
Myesha Lacy is currently the Vice President-Investor Relations at Arcellx, Inc. She previously worked as the Director-Investor Relations & Communications at Hyperion Therapeutics, Senior Director-Investor Relations at ZS Pharma, Vice President-Investor Relations & Communications at Global Blood Therapeutics, and Vice President-Investor Relations & Communications at Adverum Biotechnologies.
She completed her undergraduate degree at Holy Names University.
Cargos activos de Myesha Lacy
| Empresas | Cargo | Inicio |
|---|---|---|
| ARCELLX, INC. | Contacto de Relaciones con Inversores | 01/06/2021 |
Antiguos cargos conocidos de Myesha Lacy.
| Empresas | Cargo | Fin |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Contacto de Relaciones con Inversores | - |
| ZS PHARMA INC | Contacto de Relaciones con Inversores | - |
| HYPERION THERAPEUTICS INC | Contacto de Relaciones con Inversores | - |
| GLOBAL BLOOD THERAPEUTICS, INC. | Contacto de Relaciones con Inversores | - |
Formación de Myesha Lacy.
| Holy Names University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ARCELLX, INC. | Health Technology |
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
ZS Pharma, Inc.
 ZS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA. | Health Technology |
Hyperion Therapeutics, Inc.
 Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Myesha Lacy
